Health

Evolve Beyond Limits: YIZUMI CONNECT 2026 Showcases

FOSHAN, China, May 20, 2026 /PRNewswire/ -- Following its presence at CHINAPLAS 2026 in Shanghai, YIZUMI brought its latest vision for advanced molding and smart manufacturing to YIZUMI CONNECT 2026 in Nanxun, forming a twin-city platform linking the two events. YIZUMI CONNECT 2026: Full-Process...

2026-05-20 21:00 3957

METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026

BEIJING, HANGZHOU, China and CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a global leader in AI-powered drug delivery innovation, today announced that new preclinical data from its heart-targeted LNP program has been selected for a Late-Breaking oral presentation at the...

2026-05-20 18:57 4017

Celebrate National Physical Fitness & Sports Month: Breathe Better, Move Freely with Oxygen Support

NEW YORK, May 20, 2026 /PRNewswire/ -- May is National Physical Fitness & Sports Month, a time to celebrate staying active and prioritizing health at every stage of life.VARON

2026-05-20 14:32 3415

Hyundai Bioscience: "Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread"

SEOUL, South Korea, May 20, 2026 /PRNewswire/ -- Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus. Hyundai Bioscien...

2026-05-20 13:57 3136

Haier Biomedical Publishes 2025 Sustainability Report: Committed to Building a Platform for Technology, Industry and Social Responsibility

QINGDAO, China, May 20, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has released its 2025 Sustainability Report, providing a comprehensive overview of the company's measurable progress achieved in environmental, social, and governance...

2026-05-20 12:23 4328

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening HOUSTON, May 19, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free ...

2026-05-19 23:45 6003

ALR TECHNOLOGIES HAS LAUNCHED THE GLUCURVE PET CGM IN CANADA

SINGAPORE, May 19, 2026 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces the GluCurve Pet CGM ("GluCurve") is now for sale in Canada at www.GluCurve.ca . GluCurve is the first and only diabetic mo...

2026-05-19 20:28 3452

Acemate Launches Drill System, Bringing Scored, Targeted Training to Its AI Tennis System

HONG KONG, May 19, 2026 /PRNewswire/ -- Acemate , the AI-powered tennis training device company backed by OneRobotics (HKG: 6600), today announced its most significant soft...

2026-05-19 19:00 4204

Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects

CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and visceral fat in animal studies. The presentation also ma...

2026-05-19 13:19 4598

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

NANJING, China, May 18, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of Chi...

2026-05-19 09:35 4764

Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

* Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza * Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Accro Bio...

2026-05-19 08:00 3594

Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-05-19 08:00 4356

Major breakthrough of Sanyou Biopharmaceuticals AI-STAL

SHANGHAI, May 18, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap from "molecular treasure trove" to "intelligent engine", marking the company's entry into a new ...

2026-05-18 22:00 4478

Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6...

2026-05-18 21:15 5310

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

* Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. * Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axill...

2026-05-18 21:00 3882

Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

WILMINGTON, Del., May 18, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial for a novel biparatopic antibody targeting Thymic...

2026-05-18 19:00 3847

Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B- Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for  Obesity CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical compan...

2026-05-18 08:03 3428

LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma

SEOUL, South Korea, May 17, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partn...

2026-05-18 08:00 2227

WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index

SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), whic...

2026-05-18 08:00 2581

Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease

A nanosized extract of the plant thylakoid grana — the molecular engine behind photosynthesis — is transplanted into the eye's corneal cells, producing a key protective molecule when exposed to ambient light, opening a new front against dry eye disease SINGAPORE, May 15, 2026 /PRNewswire/ -- Wha...

2026-05-16 11:14 8041
12345678 ... 324